Apogee Therapeutics, Inc. (APGE) has announced promising one-year results from its Phase 2 APEX trial of Zumilokibart, a next-generation antibody for moderate-to-severe atopic dermatitis. The trial demonstrated that patients maintained significant improvements over 52 weeks with dosing as infrequent as every three to six months, a stark contrast to the frequent injections typically required by current therapies. The majority of participants achieved substantial reductions in eczema severity, with 75% to 85% reaching EASI-75 scores, while 86% maintained clear or nearly clear skin.
This development could signal a pivotal shift in the treatment landscape for atopic dermatitis, potentially easing the burden for patients who currently endure frequent therapies. Apogee’s CEO highlighted the sustained improvement in patient outcomes as a significant milestone, while dermatology experts noted the transformative potential of less frequent dosing.
As Apogee prepares for the next phase of trials, market professionals should monitor APGE’s stock performance closely. Following the announcement, the stock saw a notable pre-market increase of over 15%, reflecting investor optimism about the drug’s potential and its implications for future revenue streams.
Source: nasdaq.com